Botanix Pharmaceuticals
Botanix Pharmaceuticals is an Australian clinical dermatology company focused on developing and commercializing innovative treatments for common skin diseases. Their lead product candidate is Sofdra, a potential treatment for primary axillary hyperhidrosis, and they are also developing other products for acne and atopic dermatitis.
Short position
Botanix Pharmaceuticals (ASX:BOT) has 0.64% of its shares on issue reported as short positions as of 5 Oct 2026, or about 17,619,596 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has risen 0.42 percentage points. Its highest recorded short interest was 5.23% in July 2025. BOT is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Botanix Pharmaceuticals (BOT) company profile
Profile, insiders and operations
Company
AI-generated research profile of Botanix Pharmaceuticals
BOT intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links